Achromobacter xylosoxidans est un bacille à Gram négatif non fermentaire pathogène opportuniste. Il est de plus en plus fréquemment isolé chez les patients atteints de mucoviscidose, colonisant leur arbre bronchique et pouvant être responsable d’une dégradation de la fonction respiratoire. Il s’agit d’une espèce bactérienne naturellement résistante à de nombreux antibiotiques : aux céphalosporines (hors ceftazidime), à l’aztréonam et aux aminosides. Les résistances acquises sont fréquentes, en particulier dans les souches isolées d’expectorations de patients atteints de mucoviscidose. Ces résistances acquises concernent des molécules antibiotiques très utilisées pour le traitement des exacerbations respiratoires de la maladie, ce qui conduit parfois à de véritables impasses thérapeutiques. Au début de notre travail, seuls quelques mécanismes de résistance acquise aux β-lactamines avaient été décrits, mais aucun mécanisme impliqué dans la multi-résistance naturelle d’A. xylosoxidans.La résistance aux antibiotiques par efflux actif de type Resistance-Nodulation-cell Division (RND) est très répandue chez les bacilles à Gram négatif non fermentaires. Nous avons identifié dans le génome d’A. xylosoxidans trois opérons pouvant coder pour des systèmes d’efflux RND. Par une technique d’inactivation génique nous avons montré que les trois systèmes d’efflux (AxyABM, AxyXY-OprZ et AxyCDJ) pouvaient exporter des antibiotiques. Deux d’entre eux participent à l’antibio-résistance naturelle d’A. xylosoxidans : AxyABM (résistance à l’aztréonam et à plusieurs céphalosporines) et AxyXY-OprZ (résistance aux aminosides) / Achromobacter xylosoxidans is a nonfermentative Gram-negative bacillus considered to be an opportunistic agent. It is an emerging pathogen in cystic fibrosis (CF), increasingly recovered from the respiratory tract of CF patients. It can cause inflammation and therefore might be involved in the decline of the lung function.This species is innately resistant to many antibiotics, including cephalosporins (except ceftazidime), aztreonam, and aminoglycosides. Moreover the isolates recovered from CF patient sputum are often resistant to major antimicrobial components usually prescribed to treat pulmonary infections. There was very little known about acquired resistance and nothing about innate resistance mechanisms when we started this work.Antibiotic resistance mediated by Resistance-Nodulation-cell Division (RND)-type efflux pumps is widespread among nonfermentative Gram-negative bacilli. We have characterized three putative RND operons in A. xylosoxidans genome. By using a gene inactivation technique we have demonstrated that these operons encode efflux systems (AxyABM, AxyXY-OprZ and AxyCDJ) able to export antibiotics. Two of them are strongly involved in A. xylosoxidans innate antibiotic resistance: AxyABM (resistance to aztreonam and various cephalosporins) and AxyXY-OprZ (aminoglycoside resistance).

L’émergence des déterminants de résistances plasmidiques aux quinolones (PMQR), auxquels appartient le gène qnrD, participent de manière significative à la sélection des résistances de haut-niveau aux permet les réparations de l’ADN lors des stress soumis aux bactéries, et d’autre part, que les aminosides, une autre classe d’antibiotiques que les fluoroquinolones, induisaient la réponse SOS chez Escherichia coli. En effet, nous avons montré que les petits plasmides-qnrD chez E. coli, induisent la formation de monoxyde de nitrogène et l’inhibition de la voie de détoxification Hmp-dépendante. Ces processus génèrent des lésions à l’ADN qui s’ajoutent à celles occasionnées par les aminosides concourant à activer la réponse SOS chez E. coli. L’ensemble de nos résultats montrent que l’émergence de la résistance aux fluoroquinolones peut être occasionnée par l’exposition d’E. coli à une autre classe d’antibiotiques, ici les aminosides. / The emerging plasmid-mediated quinolones resistance (PMQR) determinants significantly participate in the selection of high-level of resistance to the major antibiotics fluoroquinolones, leading to numerous clinical failures. In this study, we reported for the first time that PMQR expression could be triggered by the fluoroquinolones but also by another major class of antibiotics, the aminoglycosides. We were able to show that this unique cross selection of antibiotic resistance was the consequence of the PMQR determinant qnrD being SOS-regulated in a RecA-LexA dependent manner. We demonstrated that sub inhibitory concentration of aminoglycoside induced nitric oxide formation associated with the repression of the Hmp-mediated detoxification pathway, resulting in the induction of the SOS response and thus up-regulation of the PMQR. Overall, our findings revealed an unexpected antibiotic resistance cross-selection with low aminoglycosides concentrations promoting emergence of fluoroquinolones resistance.

miRNA sind kurze 21 – 23 nukleotidlange nicht kodierende RNAs endogenen Ursprungs und regulieren auf post-transkriptionaler Ebene die Genexpression. Da aberrante Expressionsmuster der miRNAs im Zusammenhang mit verschiedenen Krankheiten stehen, ist das Interesse groß, Kontrolle über die miRNA-vermittelte Genexpression zu erhalten. Bei Krankheitsbildern, die eine Überexpression der miRNA aufweisen, kann die Inhibition der miRNA Reifung als Therapieansatz dienen. Inhibition kann z. B. durch peptidische Strukturen und durch small molecules, wie Aminoglykoside erfolgen. Ziel dieser Arbeit war die nahezu vollständig festphasenbasierte Synthese von zyklischen Peptiden und Peptid-Aminoglykosid-Konjugaten als potentielle Inhibitoren der miRNA Reifung. Ferner sollte die Guanidinylierung an fester Phase mit verschiedenen Testsubstraten gezeigt werden. In der vorliegenden Arbeit wurden im ersten Teilprojekt zehn zyklische Peptide mit Hilfe eines bisfunktionalen Linkermoleküls in den Seitenketten zweier im Peptid enthaltener Cysteine synthetisiert und isoliert. Basierend darauf wurden neun weitere zyklische Peptide an fester Phase synthetisiert, mit ausgewählten Aminoglykosiden in einer CuAAC gebunden und erfolgreich isoliert. Im zweiten Teilprojekt dieser Arbeit wurde die Guanidinylierung an fester Phase mittels des Goodman’s Reagent gezeigt. In ersten Studien wurden vier Testpeptide an fester Phase guanidinyliert. Im Anschluss wurde die Limitierung dieser Methode geprüft. Dazu wurden Aminoglykoside mittels CuAAC an verschiedene Peptid- und Peptid PNA-Rückgrate geknüpft und guanidinyliert. Nicht für alle Substrate konnte die vollständige Guanidinylierung an fester Phase gezeigt werden. Ein weiteres Teilprojekt zeigte die Funktionalisierung von kommerziell erhältlichen Polymeren für die SPPS in Hinsicht auf fluorophorbasierte „Hochdurchsatz Screening-Methoden“. Dazu wurde ein peptidischer Spacer entworfen, der eine Knüpfungsstelle für Fluorophore mittels CuAAC enthielt. / miRNA are short long non-coding RNAs endogenous origin with a length of 21 – 23 nucleotides. MicroRNAs regulate the gene expression on post-transcriptionally level. Starting in the nucleus, primary transcripts are processed into precursor-miRNAs. Accordingly, the miRNA matures after export into cytosol. Since aberrant expression patterns are related to different diseases, it’s from interest to gain control about miRNA mediated gene expression. Some diseases are related to over expression of miRNA. For that reason, the inhibition of the miRNA maturing is object of research. The inhibition can be resulted from peptide structures or with small molecules like aminoglycosides. Aim of this work was the solid phase synthesis of cyclic peptides derivatives and peptide aminoglycoside conjugates as potential inhibitors of the miRNA maturing. In addition, the guanidinylation on solid phase should be evidenced with different substrates. In the first part of the project ten cyclic peptides were synthesized on solid phase. The cyclization was carried out with a bifunctional linking molecule in the side chains of two cysteines. Based on that nine cyclic peptides were synthesized and elected aminoglycosides were bound with help of CuAAC. The second part of this work showed the guanidinylation on solid phase by using Goodman’s reagent under mild conditions. Four peptides were used for initial studies. Due to the success of this method the limit was evaluated. Therefore, aminoglycosides were bound via CuAAC to different peptide and peptide-PNA backbones. By mischance, not all the chosen substrates were fully guanidinylated on solid phase. A further short project showed the functionalization of commercially available resins for solid phase peptide synthesis in relation to fluorophore based high throughput screening methods. For this purpose, a peptide spacer was devised with a binding site for fluorophores via CuAAC.

<p>Toxic products, such as endotoxin from the gram-negative and exotoxin from the gram-positive bacteria, are the most important initiators of the inflammatory host response in sepsis. In addition to antibacterial treatment, numerous attempts have been made to interfere with the exaggerated proinflammatory cascade initiated by the toxins. As most antitoxic and anti-inflammatory agents have shown no clear efficacy, an attractive alternative has been to prevent or minimise their release. Therefore, it was of interest to further study the antibiotic-induced release of toxins after exposure to antibiotics used for the treatment of the most severe infections, especially if protein synthesis inhibitors could reduce the release induced by PBP 3-specific β-lactam antibiotics.</p><p>There were significant reductions in endotoxin release from gram-negative bacteria when the combination of the PBP 3-specific β-lactam antibiotic, cefuroxime, and the protein synthesis inhibitor, tobramycin, was compared with cefuroxime alone. Increasing doses of tobramycin reduced endotoxin release and increased the killing rate. In a kinetic <i>in vitro</i> model the endotoxin release from <i>E.coli</i> was higher after the second dose of cefuroxime. Nevertheless, it was reduced after addition of tobramycin.</p><p>No binding of tobramycin to endotoxin was observed, either <i>in vivo</i> or <i>in vitro</i>. In a porcine sepsis model, a possible anti-inflammatory effect of ceftazidime and tobramycin, expressed as late cytokine inhibition, was seen.</p><p>The protein synthesis inhibitor, clindamycin, released less streptococcal pyrogenic exotoxin A (SpeA) from a group A streptococcus strain than penicillin, and addition of clindamycin to penicillin resulted in less toxin production than penicillin alone. The SpeA production was dependent on the bacterial number at the start of treatment. Higher doses of penicillin also led to less SpeA. </p><p>The choice of antibiotic class and dose may be important in the severely ill septic patient in whom an additional toxin release could be deleterious. A combination of a β-lactam antibiotic and a protein synthesis inhibitor seems beneficial but further investigations are needed.</p>

Toxic products, such as endotoxin from the gram-negative and exotoxin from the gram-positive bacteria, are the most important initiators of the inflammatory host response in sepsis. In addition to antibacterial treatment, numerous attempts have been made to interfere with the exaggerated proinflammatory cascade initiated by the toxins. As most antitoxic and anti-inflammatory agents have shown no clear efficacy, an attractive alternative has been to prevent or minimise their release. Therefore, it was of interest to further study the antibiotic-induced release of toxins after exposure to antibiotics used for the treatment of the most severe infections, especially if protein synthesis inhibitors could reduce the release induced by PBP 3-specific β-lactam antibiotics. There were significant reductions in endotoxin release from gram-negative bacteria when the combination of the PBP 3-specific β-lactam antibiotic, cefuroxime, and the protein synthesis inhibitor, tobramycin, was compared with cefuroxime alone. Increasing doses of tobramycin reduced endotoxin release and increased the killing rate. In a kinetic in vitro model the endotoxin release from E.coli was higher after the second dose of cefuroxime. Nevertheless, it was reduced after addition of tobramycin. No binding of tobramycin to endotoxin was observed, either in vivo or in vitro. In a porcine sepsis model, a possible anti-inflammatory effect of ceftazidime and tobramycin, expressed as late cytokine inhibition, was seen. The protein synthesis inhibitor, clindamycin, released less streptococcal pyrogenic exotoxin A (SpeA) from a group A streptococcus strain than penicillin, and addition of clindamycin to penicillin resulted in less toxin production than penicillin alone. The SpeA production was dependent on the bacterial number at the start of treatment. Higher doses of penicillin also led to less SpeA. The choice of antibiotic class and dose may be important in the severely ill septic patient in whom an additional toxin release could be deleterious. A combination of a β-lactam antibiotic and a protein synthesis inhibitor seems beneficial but further investigations are needed.

Στην παρούσα διατριβή μελετήθηκε ο ρόλος της έλικας h44 του 18S rRNA του Saccharomyces cerevisiae επί διαφόρων παραμέτρων της πρωτεϊνικής σύνθεσης. Η μελέτη διεξήχθη με την βοήθεια των σημειακών μεταλλάξεων A1491G (rdn15) και U1495C (rdnhyg1), οι οποίες εντοπίζονται στην Α-θέση του ριβοσώματος. Η μετάλλαξη rdn15 επιδρά ήπια στον ρυθμό ανάπτυξης των κυττάρων ενώ τα rdn15 ριβοσώματα επιτελούν την πρωτεϊνοσύνθεση με αυξημένη ακρίβεια. Η έλλειψη σοβαρών επιπτώσεων παρουσία της rdn15 φανερώνει ότι το νουκλεοτίδιο 1491 δεν παίζει καθοριστικό ρόλο στην λειτουργία του ριβοσώματος. Τα κύτταρα ζύμης που φέρουν την μετάλλαξη rdnhyg1 αναπτύσσονται βραδύτερα από τα κύτταρα αγρίου τύπου, ενώ τα rdnhyg1 ριβοσώματα πρωτεϊνοσυνθέτουν με ελαφρώς αυξημένη συχνότητα λάθους. Η μετάλλαξη αυξάνει επίσης την συγγένεια της Α-θέσης του ριβοσώματος για το αμινοακυλο-tRNA και επιδρά αρνητικά στο στάδιο της μετατόπισης, χωρίς να επηρεάζει την ενεργότητα πεπτιδυλοτρανσφεράσης. Η επίδραση της μετάλλαξης rdnhyg1 επί διαφόρων παραμέτρων της πρωτεϊνοσύνθεσης δικαιολογεί την συντήρηση της U1495 κατά την εξέλιξη. Η μετάλλαξη sup45-R2ts εντοπίζεται στο γονίδιο που κωδικοποιεί τον παράγοντα τερματισμού eRF1 και οδηγεί στην αντικατάσταση της προλίνης 86 από αλανίνη. Η μετάλλαξη δεν επηρεάζει τις περισσότερες από τις λειτουργίες του ριβοσώματος που εξετάστηκαν, αλλά μειώνει την μεταφραστική πιστότητα. Σε κύτταρα που φέρουν ταυτόχρονα την μετάλλαξη sup45-R2ts και την ριβοσωματική μετάλλαξη rdn15, η συχνότητα λάθους αυξάνεται σε βαθμό μεγαλύτερο από την αθροιστική επίδραση των δύο επιμέρους μεταλλάξεων, επιβεβαιώνοντας μια ιδιαίτερη αλληλεπίδραση του μεταλλαγμένου παράγοντα eRF1 με τα rdn15 ριβοσώματα, που, όπως προκύπτει, αντιστρέφει τον υπερακριβή χαρακτήρα των μεταλλαγμένων ριβοσωμάτων. Όταν η μετάλλαξη sup45-R2ts συνυπάρχει με την ριβοσωματική μετάλλαξη rdnhyg1 η συχνότητα λάθους δεν επηρεάζεται σημαντικά. Η rdnhyg1 φαίνεται να ελαχιστοποιεί την επίδραση του μεταλλαγμένου παράγοντα eRF1 ενισχύοντας την δράση GTPάσης του eRF3. Τα παραπάνω αποτελέσματα φανερώνουν επιπλέον ότι η sup45 δύναται να μεταβάλει τις ιδιότητας ορισμένων μεταλλάξεων κατά την ριβοσωματική λειτουργία. Το στέλεχος που φέρει την μετάλλαξη rdn15 είναι πολύ ευαίσθητο έναντι της παρομομυκίνης αλλά και έναντι της τομπραμυκίνης, αν και σε μικρότερο βαθμό. Τα αποτελέσματα αυτά αποδίδονται στην ικανότητα της μετάλλαξης να αυξάνει την συγγένεια της Α-θέσης του ριβοσώματος για τα εν λόγω αντιβιοτικά. Αντίθετα, η μετάλλαξη rdn15 προσδίδει ανθεκτικότητα στην υγρομυκίνη, φανερώνοντας ότι ο τρόπος πρόσδεσης και δράσης του συγκεκριμένου αμινογλυκοζίτη διαφοροποιείται. Το στέλεχος που φέρει την μετάλλαξη rdnhyg1 είναι ανθεκτικό και στα τρία αντιβιοτικά σε σύγκριση με το αγρίου τύπου, φανερώνοντας ότι η U1495 είναι καθοριστική για την πρόσδεση των αμινογλυκοζιτών στο ριβόσωμα. Τα κύτταρα που φέρουν την εξωριβοσωματική μετάλλαξη sup45-R2ts είναι πιο ευαίσθητα από τα αντίστοιχα αγρίου τύπου έναντι και των τριών αμινογλυκοζιτών. Ωστόσο η μετάλλαξη sup45-R2ts, δεν επηρεάζει την ικανότητα των αντιβιοτικών αυτών να προσδένονται στα αγρίου τύπου και μεταλλαγμένα ριβοσώματα και να επάγουν άμεσα τα μεταφραστικά λάθη. Η μελέτη επίδρασης των αμινγλυκοζιτών επιβεβαίωσε ότι η παρομομυκίνη και η υγρομυκίνη αναστέλλουν την ανάπτυξη των κυττάρων ζύμης, ενώ η τομπραμυκίνη δεν έχει καμία επίδραση. Το γεγονός αυτό συνδυάζεται με την αδυναμία της τομπραμυκίνης να αναστείλει την πρόσδεση του υποστρώματος στην Α-θέση των ριβοσωμάτων. Ωστόσο η τομπραμυκίνη, όπως η παρομομυκίνη και η υγρομυκίνη, είναι ικανή να αυξήσει την συχνότητα λάθους και την σύνθεση πολυφαινυλαλανίνης. / In present study, we investigated the role of helix h44 of 18S rRNA of Saccharomyces cerevisiae on several parameters of protein synthesis. For this purpose we employed mutations A1491G (rdn15) and U1495C (rdnhyg1) which are located in the A-site of the ribosome. The rdn15 mutation slightly delays cell growth, while rdn15 ribosomes translate proteins with higher fidelity. The lack of severe impairment of ribosomal function by mutation rdn15 indicates that the nature of nucleotide 1491 is not essential for ribosomal function. Yeast cells carrying the rdnhyg1 mutation grow slower than wild-type cells, while their ribosomes possess a slightly increased error rate. This mutation also increases the affinity of the A-site for aminoacyl-tRNA and renders ribosomes less efficient in translocation without affecting peptidyltransferase activity. The effect of mutation rdnhyg1 on several parameters of protein synthesis explains why U1495 is evolutionarily conserved. Mutation sup45-R2ts is located in the gene encoding eukaryotic Release Factor 1 (eRF1) and results in the substitution of proline 86 by alanine. This mutation leaves unaffected most ribosomal functions but it decreases translational fidelity. When ribosomal mutation rdn15 is introduced in cells already carrying sup45-R2ts mutation, the error frequency is increased to a degree which is higher than the additive effect of the two mutations, testifying to a previously reported special interaction of eRF1 with rdn15 ribosomes, which in this case reverses the hyperaccurate character of rdn15 ribosomes. When mutation sup45-R2ts is expressed in cells also carrying ribosomal mutation rdnhyg1, the error frequency is not significantly altered. Mutation rdnhyg1 seems to minimize the effect of the mutant factor eRF1 on ribosomal function by enhancing GTPase activity of eRF3. The results obtained with rdn15 and rdnhyg1 alone or in combination with sup45-R2ts show for the first time that the presence of sup45 may result in significant changes in the properties of the mutations under study. The strain carrying mutation rdn15 exhibits extremely high sensitivity toward paromomycin and also increases sensitivity of yeast ribosomes to tobramycin but to a lesser degree. These results demonstrate the ability of this mutation to increase affinity of the A-site for aminoglycosides. In contrast, mutation rdn15 causes resistance to hygromycin, revealing that binding and possibly action of hygromycin is differentiated from the other two aminoglycosides. The strain carrying mutation rdnhyg1 is resistant to all three antibiotics tested compared to wild type, indicating that U1495 participates in aminoglycoside binding to the ribosome. Cells carrying the extraribosomal mutation sup45-R2ts are more sensitive toward all three antibiotics compared to their wild type cells. Nevertheless, mutation sup45-R2ts does not affect the ability of these antibiotics to bind to the ribosome and directly induce translational errors. The study of amingolycoside action confirmed that paromomycin and hygromycin inhibit cells growth, while no such effect is observed during cell growth in the presence of tobramycin. This fact is combined with the inability of tobramycin to inhibit substrate binding to the ribosomal A-site Nevertheless, it was shown that tobramycin, like paromomycin and hygromycin, is effective both in inducing translational errors and increasing polyphenylalanine synthesis in wild-type and mutant ribosomes.

Antibiotics are among the most commonly prescribed drugs. Although the majority of these drugs were developed several decades ago, optimal dosage (dose, dosing interval and treatment duration) have still not been well defined. This thesis focuses on the development and evaluation of pharmacometric models that can be used as tools in the establishment of improved dosing strategies for novel and already clinically available antibacterial drugs. Infectious diseases are common causes of death in preterm and term newborn infants. A population pharmacokinetic (PK) model for gentamicin was developed based on data from a prospective study. Body-weight and age (gestational and post-natal age) were found to be major factors contributing to variability in gentamicin clearance and therefore important patient characteristics to consider for improved dosing regimens. A semi-mechanistic pharmacokinetic-pharmacodynamic (PKPD) model was also developed, to characterize in vitro bacterial growth and killing kinetics following exposure to six antibacterial drugs, representing a broad selection of mechanisms of action and PK as well as PD characteristics. The model performed well in describing a wide range of static and dynamic drug exposures and was easily applied to other bacterial strains and antibiotics. It is, therefore, likely to find application in early drug development programs. Dosing of antibiotics is usually based on summary endpoints such as the PK/PD indices. Predictions based on the PKPD model showed that the commonly used PK/PD indices were well identified for all investigated drugs, supporting that models based on in vitro data can be predictive of antibacterial effects observed in vivo. However, the PK/PD indices were sensitive to the study conditions and were not always consistent between patient populations. The PK/PD indices may therefore extrapolate poorly across sub-populations. A semi-mechanistic modeling approach, utilizing the type of models described here, may thus have higher predictive value in a dose optimization tailored to specific patient populations.

No description available.

No description available.

Adjacent cells communicate through gap junctions (GJs). These GJs are formed by head to head docking of two hemichannels (HCs) from two adjacent cells. HCs are connexin hexamer proteins. Connexin mutation is the most frequent cause of childhood hearing loss. This hearing impairment affects 2 in every 2000 children. Inhibition of the HCs might be the key factor to treat such disorders. A library of amphiphilic kanamycins was synthesized to be tested as HC inhibitors. These compounds showed excellent inhibition activity in comparison with the parent compound (kanamycin A) with less toxicity. A library of monosaccharide esters with varying carbon chain lengths (acetyl (C2) to hexadecyl (C16)) were synthesized, characterized, and tested for bioactivity. Carbohydrate esters showed low toxicity while remaining active against bacteria and fungi. The compound 6-O-tetradecanoyl-D-mannopyranose (MAN014), a mannose ester with a fourteen-carbon chain, showed the greatest antibacterial and antifungal properties. A mode of action study was tested against Staphylococcus aureus (bacteria) and Fusarium graminearum (fungus) and found the compound perturbed the cell membrum.